AHA GUIDELINES Bundle (free trial)

Dyslipidemia 2026

AHA GUIDELINES Apps brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1543908

Contents of this Issue

Navigation

Page 29 of 105

30 Management 4.2.3.2. PREVENT-ASCVD Equations COR LOE Recommendation 1 B-NR 1. In adults aged 30 to 79 years without ASCVD or subclinical atherosclerosis and with an LDL-C level between 70 and 189 mg/dL (1.8–4.9 mmol/L), the PREVENT-ASCVD equations should be used to estimate 10-year ASCVD risk, with categorization as having low (<3%), borderline (3% to <5%), intermediate (5% to <10%), or high (≥10%) 10-year estimated ASCVD risk. Table 11. Salient Features of the American Heart Association PREVENT™* Equations The PREVENT equations: 1. Included a large, contemporary, representative sample of U.S. adults for derivation (N ~3.3 million) and external validation (N ~3.3 million). 2. Lower limit to begin risk prediction to age 30 years (through 79 years). 3. Provide sex-specific equations; race/ethnicity is not a variable that added predictive value to the equations and provides estimates adjusted for competing risk of non- CVD death. 4. Provide a base model for risk prediction that includes commonly available risk factor measures: age, sex, blood pressure, total and HDL-C, diabetes status, tobacco use, kidney function (eGFR), statin use, and antihypertensive medication use (and BMI for heart failure prediction). 5. Provide optional models with additional inputs, if known/measured, of hemoglobin A1c (to capture glycemic status), urinary albumin/creatinine ratio (for proteinuria and CKD), and zip code (to represent social deprivation index and acknowledge social determinants of cardiovascular risk). These factors are not necessary to generate risk estimates, but they may enhance risk prediction if available. 6. Predict 10-year and 30-year outcomes. 7. Predict risk for hard ASCVD † (relevant for LLT decisions), HF, and total CVD (ASCVD plus HF; relevant for blood pressure-lowering therapy decisions).

Articles in this issue

Archives of this issue

view archives of AHA GUIDELINES Bundle (free trial) - Dyslipidemia 2026